OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

ModifiedColorado Rocky Mountain Health PlansPolicy CS079OH.E

Minimally Invasive Procedures for the Treatment of Upper Gastrointestinal Diseases (for Ohio Only)

Customize your policy alerts

Sign up for Colorado Rocky Mountain Health Plans Policy CS079OH.E alerts

Get alerted when Policy CS079OH.E changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Ohio-specific policy governing coverage and medical necessity criteria for minimally invasive procedures to treat upper GI disorders (GERD, achalasia, gastroparesis) for Colorado Rocky Mountain Health Plans members in Ohio.

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyMinimally Invasive Procedures for the Treatment of Upper Gastrointestinal Diseases (for Ohio Only)

Policy CodePolicy CS079OH.E

Change TypeRevised language clarifying GERDx® wordingsupporting sections refreshed

Effective DateAug 1, 2026

Last ReviewAug 1, 2026

Next Review Date

Key ActionSubmit prior authorization with clinical rationale, prior therapy history, and validated symptom scores for POEM/G-POEM/Z-POEM and novel endoscopic GERD procedures.

SourceLink

POLICY UPDATE CHANGES

Replaced language that GERDx® was 'investigational, unproven, and not medically necessary ... has not received FDA approval' with 'endoluminal therapy with GERDx® is unproven and not medically necessary for treating Gastroesophageal Reflux Disease'.

Updated Description of Services, Clinical Evidence, and References sections to reflect the most current information.

Ohio-onlystate scope

CPT listedprocedure codes provided

90%POEM clinical success

70%G-POEM ~1-yr success

Insufficientevidence quality (Zenker/GERD endoscopic)

Coverage and Medical Necessity Criteria

Gastric Electrical Stimulation

Covered when ALL of the following are met:

Gastric electrical stimulation (GES): GES is proven and medically necessary for treating refractory gastroparesis that has failed other therapies or chronic, intractable (drug-refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology.failure of other therapies

Refer to InterQual CP: Procedures, Gastric Stimulation for detailed clinical criteria.

Pyloroplasty

Covered when ALL of the following are met:

Pyloroplasty: Surgical pyloroplasty (open or laparoscopic) is proven and medically necessary for treating refractory gastroparesis that has failed other therapies or chronic, intractable (drug-refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology.failure of other therapies

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyMinimally Invasive Procedures for the Treatment of Upper Gastrointestinal Diseases (for Ohio Only)

Policy CodePolicy CS079OH.E

Change TypeRevised language clarifying GERDx® wordingsupporting sections refreshed

Effective DateAug 1, 2026

Last ReviewAug 1, 2026

Next Review Date

Key ActionSubmit prior authorization with clinical rationale, prior therapy history, and validated symptom scores for POEM/G-POEM/Z-POEM and novel endoscopic GERD procedures.

SourceLink

On This Page

Applies to adults and members under 18 as stated.

Peroral endoscopic myotomy (POEM)

Peroral endoscopic myotomy (POEM) coverage:

POEM for Achalasia or Diffuse Esophageal Spasm: POEM is proven and medically necessary for treating individuals with Achalasia or Diffuse Esophageal Spasm.clinical diagnosis of achalasia or diffuse esophageal spasm

POEM requires advanced endoscopic expertise and is supported by randomized and guideline evidence (see Werner et al. and AGA practice update).

POEM other indications: POEM is unproven and not medically necessary for all other indications (e.g., Zenker diverticula) due to insufficient evidence of efficacy.other indications

Z-POEM and other experimental indications lack high-quality comparative data and long-term follow-up.

GERD endoscopic/device therapies

Endoscopic and device therapies for GERD:

G-POEM: Gastric POEM (G-POEM) is unproven and not medically necessary for the treatment of gastroparesis.g-POEM indication gastroparesis

Evidence quality is low and long-term durability and safety remain uncertain.

GERD endoscopic therapies considered unproven: The following are unproven and not medically necessary for treating GERD due to insufficient evidence of efficacy: endoscopic therapies other than transoral incisionless fundoplication, injection or implantation techniques, LINX Reflux Management System, and endoluminal therapy with GERDx.GERD indications

TIF/EsophyX is considered separately in evidence summaries; other endoscopic approaches are not established as standard therapy.

Evidence-informed coverage groups

Coverage considerations informed by evidence and guideline excerpts in the document portion:

GES coverage considerations: Consider GES for medically refractory diabetic or idiopathic gastroparesis after failure of standard medical therapy; document prior therapies and refractory symptoms.ACG conditional recommendation; failure of standard therapy

Guidelines describe GES as a Humanitarian Use Device with low-quality evidence; removal and conversion rates and inconsistent trial results should be considered in selection and counseling.

Pyloroplasty consideration: Pyloroplasty (alone or with fundoplication) has reported success rates ranging approximately 61–86% and may provide more consistent symptom relief than GES; consider pyloric intervention in appropriate candidates and document rationale.systematic review findings

Systematic reviews report favorable symptom and gastric emptying outcomes for pyloroplasty.

POEM coverage considerations for achalasia: POEM demonstrates comparable clinical success to laparoscopic Heller myotomy in randomized trials (e.g., Werner et al. noninferiority RCT with 2-year Eckardt success ~83%) and is an accepted alternative for achalasia treatment; counsel patients about increased post-POEM reflux risk.Eckardt ≤ 3 for success

Multiple systematic reviews support POEM efficacy especially for type III achalasia; operator experience and reflux management are important considerations.

POEM (esophageal) — supported evidence

Evidence-supported indications and considerations summarized from clinical studies and guidelines

POEM for achalasia: Use of POEM is supported by randomized and systematic evidence demonstrating noninferiority to laparoscopic Heller myotomy for achalasia (Werner et al., 2019) with symptomatic success at 2 years; POEM is supported in guidelines as effective for type I/II achalasia and preferred for type III.Eckardt score ≤ 3 for success

Monitor and manage increased gastroesophageal reflux after POEM.

Zenker POEM (Z-POEM) — experimental/limited

Zenker diverticulum — evidence and limitations

Z-POEM vs flexible/rigid septotomy: Comparative observational data suggest Z-POEM may have similar or higher clinical success than flexible endoscopic septotomy, but evidence is limited by retrospective designs, variable definitions of success, and short follow-up; long-term comparative effectiveness and safety remain uncertain.limited comparative data

Larger prospective studies with standardized outcomes are needed before routine coverage for Z-POEM can be endorsed.

Gastric POEM (G-POEM) — promising but low-quality evidence

G-POEM for refractory gastroparesis — variable evidence

G-POEM: Systematic reviews and a small RCT indicate G-POEM may produce symptomatic improvement in a proportion of patients with refractory gastroparesis (approx. 70% at 1 year in some reviews; small RCT showed superiority vs sham at 6 months), but overall evidence quality is low and long-term durability and safety remain uncertain.varied GCSI improvement metrics (≥50% reduction or ≥1-point reduction)

Consider specialized center experience and ongoing trials; routine coverage is not supported by current evidence.

Endoscopic GERD therapies — unproven

Endoscopic GERD therapies (including Stretta)

Endoscopic GERD therapies: Endoscopic therapies for GERD are considered unproven and not medically necessary due to insufficient and low-quality evidence, small single-center studies, short follow-up, and inconsistent objective reflux control.insufficient evidence

Technique-specific summaries (e.g., Stretta, EFTP, MUSE) are provided in subsequent entries.

General stance

General coverage stance for endoscopic GERD therapies in this document:

Overall evidence stance: Endoscopic therapies for GERD (including Stretta radiofrequency, endoscopic plication/suturing, EFTP, and MUSE) are considered unproven due to insufficient and low-quality evidence regarding efficacy and long-term safety.

Procedures listed as unproven may be considered not medically necessary when submitted as routine therapy without strong supporting evidence or trial enrollment.

Stretta (radiofrequency)

Radiofrequency energy (Stretta):

Stretta evidence summary: Multiple small studies and meta-analyses report possible symptom improvement and reduced PPI use after Stretta, but randomized sham-controlled trials (e.g., Zerbib 2020) and HTA assessments conclude evidence is low quality and insufficient to demonstrate effectiveness compared with laparoscopic fundoplication.insufficient comparative evidence

Hayes HTA and ECRI reviews note substantial uncertainty; sham RCT (n=62) showed no significant benefit on key outcomes.

Endoscopic plication/suturing (EFTP, EndoCinch, GERDx)

Endoscopic plication / suturing (EndoCinch, EFTP, GERDx, others):

EFTP/Endo plication evidence: Randomized trials and meta-analyses report symptomatic improvement and reduced PPI use in some studies (e.g., Kalapala RCT), but many studies are small, have inconsistent objective reflux outcomes, and show loss of effect over time; long-term durability and comparative effectiveness versus surgical fundoplication remain uncertain.mixed symptomatic and objective outcomes

Device availability and variable study quality limit broader coverage; GERDx is explicitly stated as unproven and not medically necessary.

MUSE (TIF by stapling)

MUSE / TIF:

MUSE evidence: Studies report symptomatic reduction and decreased PPI use in many participants after MUSE/TIF, with some maintained benefit at multi-year follow-up, but trials are small, often uncontrolled, and severe complications (including perforation) have been reported; safety and long-term effectiveness are not fully established.limited evidence and safety concerns

Testoni 2022 (n=46) reported ~two-thirds efficacy with two severe complications; larger controlled trials are needed.

Coverage-relevant evidence summaries

Summary of clinical evidence and limitations relevant to coverage decisions

Endoscopic plication/suturing (MUSE, EsophyX/TIF): Multiple case series, RCTs, and systematic reviews report symptomatic improvement and reductions in PPI use after TIF and MUSE, with some long-term follow-up showing sustained benefit in a subset of patients; limitations include heterogeneous study quality, small samples, lack of long-term comparative data to laparoscopic fundoplication, and occurrence of serious adverse events in some reports.evidence mixed

Further high-quality randomized and long-term comparative studies are required before broader coverage may be supported.

Polymer injection/implantation techniques (Durasphere, Plexiglas): Available evidence is limited to small case series and is insufficient to establish long-term safety and effectiveness; these techniques remain unproven.insufficient evidence

Early reports show possible symptom and medication reduction but lack controls and long-term data.

LINX / MSA: MSA (LINX) shows promising short-term symptom control and high PPI discontinuation rates but long-term safety, device durability, and risks (dysphagia, erosion, explantation) require further high-quality comparative data.emerging but unproven long-term

Systematic reviews recommend further RCTs with long-term follow-up.

Endoscopic plication and related device therapies for GERD are addressed explicitly in the policy. The policy lists the LINX Reflux Management System and endoluminal plication/suturing approaches (including GERDx™) among techniques considered in the evidence review, and it describes characteristics of LINX (magnetic bead ring implanted laparoscopically) and the device intent as background for coverage consideration.

The policy therefore treats these techniques as distinct categories when assessing medical necessity: endoscopic plication/suturing, injection/implantation techniques, and magnetic sphincter augmentation (LINX) are all discussed as therapies for GERD whose evidence and long-term outcomes require evaluation before coverage determination.

The document section does not set out a separate list of explicit exclusions beyond the clinical statements; however, an external Hayes Health Technology Assessment is cited noting uncertainty in efficacy for some therapies and inconsistent randomized data, which the policy uses to justify classifying techniques as unproven or not medically necessary in the absence of stronger evidence.

A recent revision clarified policy language but preserved the unproven/not medically necessary stance for specific therapies (see GERDx® wording change), reflecting continued concerns raised by HTA findings about the quality and consistency of the evidence.

The policy states that endoscopic therapies for GERD are unproven because available studies are generally small, single-center, heterogeneous, often nonrandomized or at high risk of bias, and lack long-term durability and objective reflux control data; this conclusion applies across techniques such as radiofrequency (Stretta), plication/suturing, and other endoluminal approaches.

For endoscopic plication/suturing specifically, the policy notes limited quality evidence, inconsistent definitions of adequate PPI optimization, and short follow-up, supporting the overall characterization that these endoscopic GERD therapies remain unproven.

The policy uses investigational/unproven language to imply that procedures lacking adequate evidence may be excluded from coverage. It states that techniques characterized as unproven because of insufficient or low-quality evidence could be treated as investigational and thus not eligible for routine coverage unless stronger supporting clinical data are provided.

For polymer injection and implantation techniques (specifically Plexiglas and Durasphere), the policy indicates that the available evidence is insufficient to consider these procedures proven effective and safe, and that additional randomized studies are warranted before they can be considered established therapies for GERD.

The policy reproduces FDA label information for the Enterra gastric electrical stimulation system for informational purposes and notes contraindications from the label. Based on the FDA Humanitarian Device Exemption and labeling, the Enterra device should not be used in patients with gastric obstruction or pseudo-obstruction, prior gastric resection, prior fundoplication, eating disorders, history of seizures, primary swallowing disorders, chemical dependency, or psychogenic vomiting.

The policy notes that Durasphere is FDA-approved for urethral bulking in women and that its use for esophageal reflux would be considered off‑label. Evidence for Durasphere in GERD is limited to small case series and therefore does not establish effectiveness or safety for reflux indications.

Endoluminal therapy with GERDx® is unproven and not medically necessary for treating Gastroesophageal Reflux Disease. This revised wording replaces prior phrasing that referenced FDA approval status while preserving the policy determination that GERDx® is not established as medically necessary for GERD.

Peroral endoscopic myotomy (POEM) is supported and considered proven and medically necessary for Achalasia and Diffuse Esophageal Spasm, but the policy explicitly states that POEM is unproven and not medically necessary for other indications (for example, Zenker diverticula) due to insufficient evidence of efficacy.

The body of evidence for gastric electrical stimulation (GES) is described as inconsistent and of overall low quality. The policy cites systematic reviews and HTA findings that randomized trials provide limited confirmation of benefits seen in unblinded studies, and that device removal and conversion rates and serious complications have been reported, supporting a cautious coverage approach.

The policy enumerates multiple GERD procedures and devices that are considered unproven and therefore may be not medically necessary when proposed as routine therapy without robust supporting evidence. Examples include radiofrequency (Stretta), endoscopic plication/suturing (EFTP, EndoCinch, GERDx), injection/implantation techniques, MUSE/TIF variants, and other endoluminal therapies outside of well-established fundoplication approaches.

Taken together, the policy rationale is that endoscopic therapies for GERD are not established as medically necessary because evidence is limited, heterogeneous, often of low quality, and lacks long-term objective reflux control. Therefore these procedures remain investigational pending higher-quality randomized data with longer follow-up and consistent objective outcome measures.

The policy reiterates that evidence is insufficient for polymer injection/implantation techniques such as Plexiglas and Durasphere, and that long-term effectiveness and safety for LINX (magnetic sphincter augmentation) have limited data. These evidence gaps support labeling these approaches as unproven or not established for routine coverage.

For quick reference and consistency across the document, the policy reaffirms that endoluminal therapy with GERDx® is unproven and not medically necessary for the treatment of Gastroesophageal Reflux Disease — this statement is preserved in the revised policy language to maintain clarity of coverage stance.

Procedure and Regulatory Codes

Applicable Procedure CPT CodesCPT

43210	Esophagogastroduodenoscopy, flexible, transoral; with esophagogastric fundoplasty, partial or complete, includes duodenoscopy when performed.
43257	Esophagogastroduodenoscopy, flexible, transoral; with delivery of thermal energy to the muscle of lower esophageal sphincter and/or gastric cardia, for treatment of gastroesophageal reflux disease.
43284	Laparoscopy, surgical, esophageal sphincter augmentation procedure, placement of sphincter augmentation device (i.e., magnetic band), including cruroplasty when performed.
43289	Unlisted laparoscopy procedure, esophagus.
43497	Lower esophageal myotomy, transoral (i.e., peroral endoscopic myotomy [POEM]).
43499	Unlisted procedure, esophagus.
43647	Laparoscopy, surgical; implantation or replacement of gastric neurostimulator electrodes, antrum.
43648	Laparoscopy, surgical; revision or removal of gastric neurostimulator electrodes, antrum.
43659	Unlisted laparoscopy procedure, stomach.
43881	Implantation or replacement of gastric neurostimulator electrodes, antrum, open.

1–10 of 14

1/2

Relevant procedures discussed (no explicit codes listed in this document portion)mixed

No codes listed

No explicit CPT/HCPCS/ICD-10 codes listed in this document sectionmixed

No codes listed

Codes mentioned in this excerptmixed

No codes listed

Regulatory submission identifiers mentioned (non-billing)mixed

P100049	LINX Reflux Management System PMA number
K233240	GERDx-System 510(k) number referenced
K071651	Bard EndoCinch approval 510(k) / summary (referenced)
K071553	NDO Surgical Endoscopic Plication System 510(k) (referenced)
K092400	EsophyX2 510(k) reference in approval summary
K143634	MUSE System 510(k) approval

Regulatory numbers and references (non-billing)mixed

No codes listed

Eckardt score — treatment success metric

Eckardt score — roleValidated symptom scoring system for achalasia used to assess treatment response; trials often define clinical success using this score.

Common success definitionTreatment success frequently defined as Eckardt score ≤ 3 in cited randomized trials and systematic reviews.

Use in follow-upEckardt score measured at multiple timepoints (eg, 3, 6, 12, 24 months) to monitor durable response after interventions like POEM.

Eckardt score success threshold

Numeric thresholdEckardt ≤ 3

ContextUsed as the primary success threshold in randomized trials (Werner et al. used ≤3 at 2 years).

ApplicationDefines clinical success for achalasia interventions such as POEM and LHM in evidence summaries.

GCSI improvement thresholds used in trials

GCSI — trial success examplesMartinek RCT defined treatment success as ≥50% reduction in total GCSI.

Uniform criterion in reviewsSome systematic reviews applied a 1‑point reduction in GCSI as a uniform clinical success criterion across heterogeneous studies.

Use caseGCSI used as the primary patient‑reported outcome to evaluate symptomatic response after G‑POEM or pyloric interventions.

BMI cutoff in MUSE study inclusion

BMI enrollment cutoffBody mass index < 40 kg/m2

Study contextIn Testoni et al. (MUSE) inclusion criteria required participants to be >18 and <70 years and have BMI <40 kg/m2.

ImplicationBMI threshold reflects common trial eligibility limiting applicability to individuals with obesity class III or higher.

Prior Authorization, Documentation, and Operational Guidance

Prior Authorization

Referenced procedure codes — submit exact codes from policy

Applicable procedure CPT and related codes are listed in the policy for reference; verify and submit the exact code(s) from the policy (e.g., 43210, 43257, 43284, 43497, 43647, 43648, 43881, 43882, 64590, 64595) when requesting authorization and follow plan rules for prior authorization determination.

Use the policy’s Applicable Codes list when preparing prior authorization requests.
Listing of a code in the policy does not guarantee coverage; benefit determination follows federal, state, or contractual requirements.

Prior Authorization

GES — prior authorization should document refractory disease and prior therapies

Clinical guidance notes that gastric electrical stimulation (GES) may be considered as a Humanitarian Use Device for medically refractory diabetic or idiopathic gastroparesis; prior authorization should require documentation of refractory symptoms and failure of standard therapies per guideline expectations.

ACG states GES may be considered for medically refractory diabetic or idiopathic gastroparesis (conditional recommendation).
AGA guidance recommends consideration of GES after failure of standard therapy; document prior medical therapy trials.

Prior Authorization

Prior authorization recommended for POEM/G-POEM/Z-POEM and novel endoscopic GERD procedures

For POEM (including esophageal POEM), G-POEM, and Z-POEM, and for novel endoscopic GERD procedures with limited evidence, the policy implies prior authorization and requests submission of clinical rationale, prior therapy history, and validated symptom scores to support medical necessity.

Providers should include diagnosis subtype, prior treatments tried, and validated symptom scores (Eckardt for achalasia; GCSI for gastroparesis) with requests.
For novel or low-evidence procedures, submit detailed clinical justification and objective testing results.

Prior Authorization

Endoscopic GERD procedures (Stretta, EFTP, MUSE) — expect prior authorization and provide evidence

Endoscopic GERD therapies such as Stretta, EFTP, and MUSE are described as unproven based on limited and low-quality evidence; prior authorization is expected and should be accompanied by supporting clinical documentation when requested.

Hayes and randomized sham-controlled trials show insufficient evidence for efficacy versus surgical fundoplication.
When prior authorization is required, include objective testing, prior PPI therapy history, and PRO measures.

Note

Prior authorization not specified here — confirm plan rules

This segment of the policy does not state explicit prior authorization rules or list affected billing codes beyond the general applicable codes section; providers must follow the applicable benefit plan’s prior authorization processes.

Policy provides codes for reference but does not itself establish plan-level prior authorization requirements in this segment.
Confirm prior authorization rules with the member’s benefit plan.

Documentation Required

Device regulatory status provided — include device details when requesting authorization

The policy lists device regulatory status (e.g., LINX PMA P100049; EsophyX2 and MUSE 510(k) summaries) for reference; device approvals may inform but do not determine prior authorization — include device and indication details if submitting.

Refer to FDA approvals/510(k)/PMA numbers provided in the policy when documenting device-based interventions.
FDA status is informational; coverage still requires medical necessity documentation.

Note

Device approvals listed — prior authorization requirements not specified

Although the policy lists FDA approvals and clearances for devices, it does not specify prior authorization requirements tied to those approvals; providers should not assume approval equals coverage and must follow benefit plan authorization processes.

The policy explicitly states FDA approval alone is not a basis for coverage.
Provide clinical justification even for FDA-cleared/approved devices.

Prior Authorization

Prior authorization governed by the member’s benefit plan and applicable law

This policy assists in interpreting standard benefit plans but states that actual prior authorization requirements are governed by the applicable benefit plan, federal, or state (Ohio Administrative Code) rules; verify and comply with those rules when seeking authorization.

Check federal, state (OAC), or contractual benefit plan requirements before submitting requests.
UnitedHealthcare may apply InterQual® criteria when applicable.

Step Therapy

Show failure of prior therapies before device or surgical interventions

Some surgical and device therapies (e.g., GES, pyloroplasty) are covered only after failure of other therapies; prior authorization and documentation must demonstrate trials of standard medical therapy and that less invasive options failed.

Document prior medical therapy failure and conservative management attempts.
Refer to InterQual® criteria where noted for detailed clinical thresholds.

Step Therapy

Preferred surgical sequence — consider pyloroplasty prior to or instead of GES

Systematic reviews and SAGES guidance indicate pyloric interventions (pyloroplasty) often provide more consistent symptom relief for refractory gastroparesis and may be considered earlier in the surgical algorithm; include rationale if requesting GES prior to pyloric intervention.

Pyloroplasty success rates reported (61–86%) and may normalize gastric emptying.
If requesting GES, document why pyloric intervention was not appropriate or was previously tried.

Step Therapy

Stepwise treatment expectation — document prior standard therapies

The policy expects a reasonable stepwise approach: standard, less-invasive, or guideline-recommended therapies should be attempted and documented before advanced endoscopic myotomy procedures are considered.

For achalasia, document prior dilation or other guideline-recommended treatments where applicable before POEM.
For gastroparesis, document optimization of medical therapy prior to G-POEM or pyloric surgery.

Step Therapy

Expect PPI optimization documented before considering endoscopic GERD procedures

Studies frequently required participants to be refractory to or dependent on PPI therapy before enrollment; prior authorization for endoscopic GERD procedures should document optimization of PPI therapy and continued symptomatic reflux despite therapy.

Document duration and dose of PPI therapy and response status.
Include objective testing (pH monitoring, endoscopy) showing ongoing pathologic reflux when available.

Note

No explicit step-therapy sequencing mandated in this policy segment

The policy does not impose explicit procedural step-therapy sequencing requirements; many studies treat procedures as alternatives to ongoing PPI therapy or to surgical fundoplication rather than as part of a mandated sequence.

Absence of explicit step-therapy rules in this excerpt means follow the member’s benefit plan for any sequencing requirements.
Provide clinical rationale if deviating from commonly expected sequencing.

Note

InterQual® and alternate guidelines may be applied to authorization reviews

UnitedHealthcare may use InterQual® criteria and other approved guidelines for utilization review; when applicable, include InterQual® references or other guideline-based documentation with prior authorization requests.

If InterQual® has applicable criteria, those may be used as the primary medical/surgical criteria.
When InterQual® does not apply, other UnitedHealthcare Medical Policies or Utilization Review Guidelines may be used.

Documentation Required

Required medical records — provide complete legible documentation

Maintain complete, legible medical records demonstrating medical necessity: relevant medical history, physical exam, prior therapies, and results of pertinent diagnostic tests must be available upon request for utilization review.

Make documentation available on request; incomplete records may delay review or lead to denial.
Include objective testing and treatment timelines tied to the requested procedure.

Documentation Required

Required clinical documentation — include etiology, prior therapy failure, and validated scores

Provider documentation must include indication (etiology: diabetic, idiopathic, postsurgical), prior medical therapy failure, objective symptom scores (e.g., PAGI-SYM, Eckardt, GCSI), and prior procedures to support selection of GES, pyloroplasty, or POEM.

For achalasia, include Eckardt score and subtype; for gastroparesis, include GCSI and gastric emptying study results.
Document prior surgical history and prior foregut surgeries as they impact device suitability.

Documentation Required

POEM/G-POEM documentation — include diagnosis subtype, severity, prior treatments, and objective testing

When requesting authorization for POEM or G-POEM, include diagnosis subtype, symptom severity, prior treatments tried, and objective testing results consistent with those used in trials to support medical necessity.

For POEM (achalasia): report Eckardt score, prior dilation or myotomy history, and manometry findings.
For G-POEM (gastroparesis): report GCSI, gastric emptying study results, and prior medical/pyloric interventions.

Documentation Required

Support requests with trial-style documentation — PROs and objective testing

Randomized sham-controlled trials and pre/post patient-reported outcome measures (e.g., GERD-HRQL) are the types of evidence referenced; include similar validated PROs and objective testing when available to support efficacy claims in authorization requests.

Include baseline and follow-up PRO scores (GERD-HRQL, RSI, GCSI, Eckardt) and relevant pH/manometry/endoscopy results.
Cite trial-based inclusion criteria (e.g., refractory to PPI) when applicable to the patient.

Documentation Required

Relevant clinical documentation for GERD procedures — include PROs and objective reflux testing

Typical clinical documentation supporting endoscopic GERD procedures includes GERD-HRQL, RSI, GERSS questionnaires, ambulatory pH monitoring, and upper endoscopy findings; include these when available to support medical necessity.

Provide GERD-HRQL and RSI scores, pH monitoring results (DeMeester or % time pH<4), and endoscopy findings (esophagitis, hiatal hernia size).
Document prior PPI therapy and response.

Documentation Required

Recommended pre-procedure diagnostic workup — include endoscopy, pH monitoring, manometry, and PROs

Pre-procedure diagnostic workup reported in cohort and registry studies commonly includes GERD-HRQL, upper endoscopy, barium swallow, ambulatory pH monitoring, and esophageal manometry; include these assessments when appropriate for the requested procedure.

Ensure diagnostic testing and questionnaires documented in the medical record prior to authorization submission.
If tests are unavailable, provide clinical rationale and alternative objective findings.

Documentation Required

Regulatory documentation links and device identifiers — include device info when relevant

The policy provides links and FDA identifiers (e.g., MUSE 510(k), LINX PMA P100049) for device documentation; include device model and regulatory information in submissions when relevant.

Cite the specific device and, if applicable, PMA or 510(k) number when documenting device-based interventions.
Remember FDA status is informational and not determinative of coverage.

Note

Check federal, state, or contractual plan rules and InterQual® applicability before submission

Before relying on this policy for coverage decisions, verify the member’s federal, state (Ohio Administrative Code), or contractual benefit plan requirements; InterQual® or other UnitedHealthcare guidelines may be applied in utilization review.

In the event of conflict, federal/state/contractual requirements govern coverage determinations.
Confirm InterQual® applicability for the requested procedure.

Denial Risk

Incomplete documentation may trigger denial — supply full medical records

Insufficient or missing medical record documentation supporting medical necessity may lead to denial of the request; ensure records fully support the requested procedure per policy and plan rules.

Provide legible, complete records of history, exam, prior therapies, and diagnostic testing.
Make documentation available upon request to avoid delays or denials.

Denial Risk

Denial/medical review risk if GES used as first-line operative therapy — justify and document prior steps

Use of GES as a first-line operative therapy may prompt utilization review because of reported conversion and device removal rates (e.g., 33.8% conversion to gastrectomy in one cohort); document why less invasive or guideline-recommended options were not appropriate.

If GES is proposed without prior pyloric intervention or other guideline-recommended steps, include justification and prior therapy documentation.
Highlight etiology (diabetic, idiopathic) and failure of standard therapies when supporting GES.

Denial Risk

Denial risk for unproven endoscopic therapies — provide strong supporting evidence

Endoscopic GERD therapies described as having insufficient or low-quality evidence (e.g., many Stretta and other endoluminal techniques) face increased risk of denial if billed as standard care without robust supporting evidence of medical necessity.

When requesting authorization for investigational/unproven procedures, include trial enrollment information or strong objective evidence to mitigate denial risk.
Highlight failure of optimized medical therapy and objective reflux testing to support necessity.

Denial Risk

Unproven procedures may be denied — do not rely on limited evidence

Procedures characterized as unproven due to low-quality or insufficient evidence may be denied as investigational; do not rely solely on device clearance or small uncontrolled studies to support routine coverage.

Policy states endoscopic GERD therapies are unproven; expect denials without adequate clinical justification.
If off-label device use is proposed, explicitly document rationale and supporting evidence.

Note

No explicit authorization triggers stated — be prepared for additional review requests

The policy does not spell out explicit authorization triggers in this section; use the clinical limitations and evidence quality notes to anticipate potential medical necessity queries during utilization review.

Be prepared to provide long-term outcome data or rationale when evidence is heterogeneous or lacking.
Anticipate requests for additional documentation where comparative or durability data are limited.

Denial Risk

Coverage not determined solely by FDA approval — document medical necessity

FDA approval or clearance is provided for informational purposes only; the policy explicitly notes FDA approval alone is not a basis for coverage — include clinical necessity documentation even for FDA-approved devices.

Example: Enterra HDE and LINX PMA are documented but do not guarantee coverage.
Off-label device use (e.g., Durasphere for esophageal reflux) should be documented as such and may be denied.

Note

Reference governing requirements — follow federal/state/contractual rules

Coverage decisions must reference federal, state (Ohio Administrative Code), or contractual requirements; failure to follow those governing rules may result in denial — verify and comply with those rules when requesting authorization.

In case of conflict, federal/state/contractual requirements govern coverage determinations.
Check plan and state rules before submitting requests.

Clinical Background and Evidence Summary

Gastroesophageal reflux disease (GERD) results from dysfunction of the lower esophageal sphincter allowing gastric contents to reflux into the esophagus; untreated GERD can cause esophagitis, strictures, Barrett metaplasia, and increase the risk of esophageal adenocarcinoma. Gastroparesis is characterized by delayed gastric emptying with symptoms such as nausea, vomiting, early satiety, and bloating and requires objective confirmation (e.g., gastric emptying scintigraphy). Achalasia is a primary esophageal motor disorder with impaired relaxation of the esophagogastric junction and loss of organized peristalsis; these clinical descriptions frame the policy’s evaluation of procedural indications and outcomes.

Coverage-relevant evidence summaries (cross-referenced here for background context)

Cross-referenced evidence summaries providing context for coverage assessments:

POEM evidence synthesis: Randomized trials and systematic reviews indicate POEM provides high short- to mid-term clinical success for achalasia (~80–90%) and is noninferior to LHM at 2 years; however, POEM is associated with higher rates of post-procedure reflux which should be discussed with patients.Eckardt ≤ 3 used as clinical success in RCTs

Evidence supports POEM for type I/II achalasia and preferential use in type III per guideline updates.

Definitions and Outcome Metrics

Achalasia — definition

DefinitionAchalasia: primary esophageal motor disorder characterized by degeneration of the myenteric plexus causing impaired relaxation of the esophagogastric junction and loss of organized peristalsis.

Source attributionDefinition cited from American Society for Gastrointestinal Endoscopy within the policy definitions section.

Clinical relevanceIdentifies patients for whom POEM and other myotomy procedures are considered appropriate therapies in the policy.

Diffuse Esophageal Spasm — definition

DefinitionDiffuse Esophageal Spasm: rare esophageal motility disorder with simultaneous, uncoordinated, or rapidly propagated contractions accompanied by dysphagia.

Source attributionDefinition cited from National Library of Medicine in the policy definitions section.

Clinical relevanceRecognized as an indication for POEM when clinically diagnosed per the policy.

Gastroesophageal Reflux Disease — definition

DefinitionGastroesophageal Reflux Disease (GERD): condition in which the lower esophageal sphincter relaxes too often or weakens, allowing stomach acid to reflux into the esophagus.

Clinical consequencesPersistent GERD may lead to esophagitis, strictures, Barrett metaplasia, and esophageal adenocarcinoma as described in the policy description.

Use in policyForms the basis for evaluating endoscopic and surgical antireflux therapies (LNF, TIF, MUSE, LINX) in coverage considerations.

Gastroparesis — definition and diagnostic reference

DefinitionGastroparesis: disorder of delayed or absent gastric emptying (delayed gastric motility), also called delayed gastric emptying.

Diagnostic referenceDiagnosis requires objective evidence of delayed gastric emptying; scintigraphy is the reference standard for measurement of gastric emptying.

Clinical featuresSymptoms include nausea, vomiting, early satiety, bloating, postprandial fullness, and epigastric pain noted in the policy description.

GES (Gastric Electrical Stimulation) — definition and context

DefinitionGastric Electrical Stimulation (GES): implantation of an electrical stimulation device that delivers pulses to the stomach to enhance gastric motility and alleviate refractory gastroparesis symptoms (eg, Enterra).

Regulatory/contextConsidered a Humanitarian Use Device in some guidance and evaluated for medically refractory diabetic or idiopathic gastroparesis per evidence summaries.

Clinical usePolicy supports GES for refractory gastroparesis after failure of standard therapies with documentation of prior treatments.

Pyloroplasty / Pyloric Intervention — definition

DefinitionPyloroplasty / Pyloric Intervention: surgical enlargement or modification of the pylorus (eg, pyloroplasty) to improve gastric emptying, performed open or laparoscopically, alone or with fundoplication or GES.

Evidence noteSystematic reviews report success rates (pyloroplasty alone ~61%; with fundoplication ~86%) and improvement in gastric emptying in a majority of patients.

Clinical roleSAGES guidance describes laparoscopic pyloroplasty as an effective surgical option for refractory gastroparesis and part of the treatment algorithm.

POEM — definition

DefinitionPOEM (Peroral Endoscopic Myotomy): endoscopic submucosal tunneling and myotomy of the esophageal sphincter performed via a peroral endoscopic approach to treat achalasia and other esophageal motility disorders.

Comparative contextCompared against laparoscopic Heller myotomy and pneumatic dilation in trials; randomized evidence shows noninferiority to LHM for achalasia at 2 years.

Technical noteRequires advanced endoscopic expertise and is considered proven and medically necessary for achalasia or diffuse esophageal spasm per the policy.

POEM — additional definition detail and context

Additional contextPOEM: used for achalasia and applied to other disorders (eg, Zenker diverticulum as Z‑POEM) though evidence for non‑achalasia indications is limited.

OutcomesClinical success commonly assessed with Eckardt score; trials report high short- to mid-term success but higher post‑procedure reflux risk compared with LHM.

Policy stancePOEM is proven and medically necessary for achalasia and diffuse esophageal spasm; other indications (eg, Zenker) are unproven per the policy.

Z-POEM — definition

DefinitionZ‑POEM (Zenker POEM): application of POEM technique (peroral endoscopic septotomy/myotomy) to treat Zenker diverticulum.

Evidence statusComparative observational studies suggest feasibility and possible higher clinical success vs flexible endoscopic septotomy, but evidence is limited and long‑term outcomes uncertain.

Policy implicationZ‑POEM is considered experimental/limited evidence in the policy pending larger prospective studies.

G-POEM — definition

DefinitionG‑POEM (Gastric POEM): endoscopic pyloromyotomy performed via peroral submucosal tunneling intended to improve gastric emptying in patients with refractory gastroparesis.

Evidence statusStudies and systematic reviews show symptomatic improvement in many patients (approx. 70% at 1 year in some reviews), but overall evidence quality is low with heterogeneity in patient selection.

Outcome measuresClinical success assessed using GCSI reductions and gastric emptying studies; trial definitions vary across studies.

Eckardt score — definition and use

DefinitionEckardt score: a validated symptom scoring system for achalasia that quantifies dysphagia, regurgitation, chest pain, and weight loss to assess severity and treatment response.

UsageUsed as the primary patient‑reported measure in achalasia trials; clinical success often defined as Eckardt ≤ 3 at follow‑up assessments.

TimingMeasured at baseline and follow‑up intervals (eg, 3, 6, 12, 24 months) in key randomized trials such as Werner et al.

GCSI — definition and use

DefinitionGCSI (Gastroparesis Cardinal Symptom Index): a patient‑reported measure used to assess severity and symptomatic response in gastroparesis studies.

Outcome applicationsUsed to define clinical success in G‑POEM and pyloric intervention studies (eg, ≥50% reduction or ≥1‑point reduction depending on the study).

Role in documentationPolicy requires GCSI scores when claiming benefit from G‑POEM or related procedures to demonstrate symptomatic improvement.

Stretta — definition

DefinitionStretta: endoscopic radiofrequency energy delivered to the gastroesophageal junction intended to reduce GERD symptoms by treating the lower esophageal sphincter and gastric cardia.

Evidence notePolicy states insufficient high‑quality evidence for safety and effectiveness; Hayes HTA found low‑quality evidence with potential but unproven benefit.

Policy stanceConsidered unproven and not established as medically necessary for routine GERD treatment in this policy excerpt without stronger evidence.

EFTP — definition

DefinitionEFTP (Endoscopic Full‑Thickness Plication) / Endoscopic plication or suturing: endoscopic suturing/plication techniques (eg, GERDx, EndoCinch) to create gastric cardia plication aimed at reducing reflux.

Evidence noteRandomized trials and meta‑analyses report symptomatic improvement and PPI reduction but long‑term durability and objective reflux control remain uncertain.

Policy stanceConsidered unproven for routine use in GERD without stronger long‑term comparative evidence.

MUSE — definition and device context

DefinitionMUSE (Medigus Ultrasonic Surgical Endostapler): a transoral endoluminal stapling device used to create an anterior partial fundoplication (TIF by MUSE) for treatment of symptomatic chronic GERD.

Regulatory contextMUSE System received 510(k) clearance for endoscopic placement of surgical staples to create anterior partial fundoplication; FDA 510(k) reference K143634 cited in the policy.

Evidence noteStudies report symptomatic improvement and reduced PPI use but are small and lack robust long‑term comparative data; severe complications reported in some series.

TIF — definition

DefinitionTIF (Transoral Incisionless Fundoplication): endoscopic fundoplication performed with devices such as EsophyX to recreate the gastroesophageal valve and reduce reflux symptoms.

Evidence noteSystematic reviews and ECRI/HTA reports indicate symptom improvement but overall evidence quality is low and further RCTs with long‑term follow‑up are warranted.

Clinical useTIF is considered among endoscopic antireflux options but the policy treats many endoscopic GERD therapies as unproven pending stronger evidence.

MUSE device (duplicate definition entry)

Regulatory noteFDA 510(k) clearance referenced; policy includes FDA document links for device information.

Evidence summaryClinical series report symptomatic benefit and PPI reduction but are limited by small size and lack of controls.

MSA / LINX — definition

DefinitionMSA (Magnetic Sphincter Augmentation) / LINX: laparoscopically implanted ring of magnetic beads placed at the gastroesophageal junction to augment the lower esophageal sphincter and reduce reflux.

Regulatory noteLINX Reflux Management System received FDA premarket approval (PMA P100049) cited in the policy.

Evidence noteSystematic reviews and cohort data show promising short‑term symptom control and PPI discontinuation but long‑term safety/durability data remain limited.

MSA — additional definition context

Additional contextMSA (magnetic sphincter augmentation): evidence includes cohort and long‑term follow‑up studies reporting symptom improvement and PPI cessation but with risks such as dysphagia and device removal in a minority of patients.

OutcomesLong‑term device removal and dysphagia rates reported; policy notes need for additional RCTs and long‑term comparative data.

Clinical implicationLINX may be considered investigational/unproven for long‑term effectiveness pending stronger evidence per policy discussion.

MUSE regulatory note (510k)

Regulatory noteMUSE System received 510(k) approval (K143634) for endoscopic stapling to create anterior partial fundoplication for symptomatic chronic GERD.

Device classificationPolicy notes these products are Class II devices and provides FDA links for device summaries.

Coverage implicationRegulatory clearance/approval information is provided for reference but not sole basis for coverage decisions.

LINX Reflux Management System — regulatory/PMA note

Regulatory/PMA noteLINX Reflux Management System: FDA premarket approval (PMA P100049) is referenced in the policy.

Device classListed alongside other endoscopic products; policy indicates device‑specific regulatory status may inform prior authorization considerations.

Evidence contextDespite PMA, the policy emphasizes need for longer‑term comparative evidence regarding safety and durability.

Durasphere — off-label use definition

DefinitionDurasphere: an injectable bulking agent FDA‑approved for urological use (stress urinary incontinence); use for esophageal reflux is off‑label.

Evidence statusAvailable evidence for esophageal applications is limited to small case series and considered insufficient to establish safety/effectiveness.

Policy implicationUse of Durasphere for GERD would be considered off‑label and could trigger noncoverage or denial without supporting evidence.

Policy Change Log

2026-08-01material_revisionLatest

Revised GERDx® wording: replaced language stating GERDx® lacked FDA approval with wording that 'endoluminal therapy with GERDx® is unproven and not medically necessary for treating Gastroesophageal Reflux Disease.'

2026-08-01supporting_sections_refreshed

Updated Description of Services, Clinical Evidence, and References sections; archived previous policy version CS079OH.D.